Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease

NEUROSCIENCE LETTERS

卷:705

Review

Miller, Silke¹  Muqit, Miratul M. K.² 

[1] Amgen Res, Neurosci Dept, 360 Binney St, Cambridge, MA 02142 USA

[2] Univ Dundee, Sch Life Sci, MRC Prot Phosphotylat & Ubiquitylat Unit, Dow St, Dundee DD1 5EH, Scotland

关键词: Parkinson's disease;    Mitophagy;    PINK1;    Parkin;    USP30;    Small molecule;   

DOI  :  10.1016/j.neulet.2019.04.029

来源: Elsevier

【 摘 要 】

The discovery of rare familial monogenic forms of early-onset Parkinson's disease has led to the identification of a mitochondrial quality control process as a key player in this disease. Loss-of-function mutations in the genes encoding PINK1 or Parkin result in insufficient removal of dysfunctional mitochondria through autophagy, a process termed mitophagy. Understanding the mechanism of this process and the function of its two key players, PINK1 and Parkin, has led to the discovery of new therapeutic approaches. Small molecule activators of mitophagy, either activating PINK1 or Parkin directly or inhibiting Parkin's counterplayer, the ubiquitin-specific protease USP30, are in preclinical development. To enable clinical success of future small molecule mitophagy enhancers, biomarkers for mitochondrial integrity and mitophagy are being developed. Only a few years after the discovery of mitophagy deficits in Parkinson's disease, research of the underlying mechanisms, drug discovery of modulators for this mechanism and identification of biomarkers provide new avenues towards the development of disease-modifying therapies.

【 授权许可】

Free